Accelerate Diagnostics (NASDAQ:AXDX) Issues Quarterly Earnings Results

Accelerate Diagnostics (NASDAQ:AXDX) released its earnings results on Thursday. The medical research company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.13, Zacks reports. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $3.00 million.

Accelerate Diagnostics Trading Down 6.2 %

Shares of NASDAQ AXDX traded down $0.07 during mid-day trading on Friday, reaching $1.06. 156,774 shares of the company’s stock were exchanged, compared to its average volume of 59,715. The firm has a market capitalization of $26.55 million, a price-to-earnings ratio of -0.37 and a beta of 0.55. The business has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.45. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $2.09.

Analyst Ratings Changes

Several research firms have weighed in on AXDX. BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com began coverage on Accelerate Diagnostics in a research report on Monday, March 17th. They set a “hold” rating on the stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.